Pyrazolopyrimidine derivatives as cyclin-dependant kinase inhibitors

by Lamie, Phoebe F.
State: New
$78.99
VAT included - FREE Shipping
Lamie, Phoebe F. Pyrazolopyrimidine derivatives as cyclin-dependant kinase inhibitors
Lamie, Phoebe F. - Pyrazolopyrimidine derivatives as cyclin-dependant kinase inhibitors

Do you like this product? Spread the word!

$78.99 incl. VAT
Only 1 items available Only 1 items available
Delivery: between 2021-06-28 and 2021-06-30
Sales & Shipping: Dodax

Check other buying options

1 Offer for $78.99

Sold by Dodax EU

$78.99 incl. VAT
State: New
Free Shipping
Delivery: between 2021-06-28 and 2021-06-30
View other buying options

Description

This book contains both review and synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as cycline dependent kinase inhibitors (CDKIs). Moreover, cytotoxic activity for the newly synthesized compounds were evaluated, specially on breast cancer cell line (MCF-7). The results obtained were compared with methotrexate as a reference drug. Docking study and molecular modeling were also done using MOE program. I hope this work to be helpful and a starting point for much more new compounds with better activity to help in treatment of such a big terrible disease like cancer. Author: Phoebe F. Lamie

Contributors

Author:
Lamie, Phoebe F.

Further information

Biography Artist:
I'm a Lecturer of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni Suef University,Egypt.I was born in Beni Suef city, Egypt in 1981.I completed my studies as a pharmacist in 2003.I was a demonstrator and then assistant lecturer in the Faculty of Pharmacy, Beni Suef University,Egypt from 2004-2013.Since Feb. 2013,I'm a lecturer.
Language:
Englisch
Number of Pages:
248
Media Type:
Taschenbuch
Publisher:
LAP Lambert Academic Publishing

Master Data

Product Type:
Paperback book
Release date:
February 26, 2016
Package Dimensions:
0.22 x 0.15 x 0.014 m; 0.417 kg
GTIN:
09783659792991
DUIN:
AO7GGJNBQGH
$78.99
We use cookies on our website to make our services more efficient and more user-friendly. Therefore please select "Accept cookies"! Please read our Privacy Policy for further information.